The extended spectrum of RAS‐MAPK pathway mutations in colorectal cancer
| Autor: | Danielle C. Costigan, Fei Dong |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Neuroblastoma RAS viral oncogene homolog Cancer Research Colorectal cancer Biology medicine.disease_cause GTP Phosphohydrolases Proto-Oncogene Proteins p21(ras) 03 medical and health sciences 0302 clinical medicine MAP2K1 Databases Genetic Biomarkers Tumor Genetics medicine Humans HRAS Gene Membrane Proteins medicine.disease PTPN11 030220 oncology & carcinogenesis Mutation ras Proteins Mutation testing Cancer research Female KRAS Mitogen-Activated Protein Kinases Colorectal Neoplasms Signal Transduction |
| Zdroj: | Genes, Chromosomes and Cancer. 59:152-159 |
| ISSN: | 1098-2264 1045-2257 |
| DOI: | 10.1002/gcc.22813 |
| Popis: | Current clinical guidelines recommend mutation analysis for select codons in KRAS and NRAS exons 2, 3, and 4 and BRAF V600E to guide therapy selection and prognostic stratification in advanced colorectal cancer. This study evaluates the impact of extended molecular testing on the detection of RAS-MAPK pathway mutations. Panel next-generation sequencing results of colorectal cancer specimens from 5795 individuals from the American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange (AACR Project GENIE) were included. Mutations in RAS-MAPK pathway genes were analyzed and functionally annotated. Colorectal cancers had recurrent pathogenic pathway activating mutations in KRAS (44%), NRAS (4%), HRAS ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text